The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva, an ultra-rare disorder in which bone forms in soft tissue such as muscles and tendons. This makes it the third approved therapy for the condition, but Mirum says the pill offers advantages over the two previously approved products.
Atebrioz was originally developed by Incyte, and Mirum acquired the drug from that company earlier this year. The approval adds to Mirum's rare-disease portfolio, though the company will now face the challenge of commercializing a treatment for a very small patient population.
Because the source is a single report, no independent comparisons are available. The article does not detail the specific advantages Atebrioz holds over the other FOP drugs, nor does it mention pricing, efficacy data, or expected launch timing.